Aligos Therapeutics ALGS

Jump To Section

    $

    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    .
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    -$0.43 (-3.19%)Past DayToday's Volume:
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0

    Relative Strength Index (RSI)

    - The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

    - The RSI is calculated using the following formula:

    RSI = 100 - (100 / (1 + RS))

    Where RS is the ratio of the average gains to the average losses over a specified period.

    - The default time period used is 14 days.

    - RSI values range between 0 and 100.

    RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

    RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

    RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

    About

    Business overview of Aligos Therapeutics (ALGS)
    Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.

    Key Insights

    Critical company metrics and information

    • Latest Closing Price

      $12.94

    • Market Cap

      $46.43 Million

    • Price-Earnings Ratio

      0.51

    • Total Outstanding Shares

      3.46 Million Shares

    • Total Employees

      68

    • Dividend

      No dividend

    • IPO Date

      October 16, 2020

    • SIC Description

      Biological Products, (no Disgnostic Substances)

    • Primary Exchange

      NASDAQ

    • Type

      Common Stock

    • Headquarters

      One corporate dr., 2nd floor, South san francisco, CA, 94080

    • Homepage

      https://www.aligos.com

    Historical Stock Splits

    If you bought 25 shares of ALGS before August 19, 2024, you'd have 1 share today.
    Execution DateSplit Amount
    August 19, 20241-for-25 (Reverse Split)

    Cash Flow Statement

    October 1, 2023 to September 30, 2024
    MetricValue
    Net Cash Flow From Operating Activities$-85.00 Million
    Net Cash Flow$-35.06 Million
    Net Cash Flow From Financing Activities, Continuing$88.19 Million
    Net Cash Flow From Investing Activities$-38.26 Million
    Net Cash Flow From Operating Activities, Continuing$-85.00 Million
    Net Cash Flow From Investing Activities, Continuing$-38.26 Million

    Income Statement

    October 1, 2023 to September 30, 2024
    MetricValue
    Diluted Average Shares$68.79 Million
    Basic Earnings Per Share$25.39
    Basic Average Shares$68.79 Million
    Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0
    Income Tax Expense/Benefit$274,000
    Net Income/Loss$-76.95 Million

    Comprehensive Income

    October 1, 2023 to September 30, 2024
    MetricValue
    Comprehensive Income/Loss Attributable To Noncontrolling Interest$0
    Other Comprehensive Income/Loss$-76.87 Million
    Comprehensive Income/Loss$-76.87 Million
    Other Comprehensive Income/Loss Attributable To Parent$80,000
    Comprehensive Income/Loss Attributable To Parent$-76.87 Million

    Balance Sheet

    October 1, 2023 to September 30, 2024
    MetricValue
    Noncurrent Assets$8.60 Million
    Cash$74.90 Million
    Equity Attributable To Noncontrolling Interest$0
    Other Current Assets$4.92 Million
    Equity$50.10 Million
    Wages$4.41 Million

    Historical Dividends

    Announcement DatePayment DateRecord DateAmountFrequency
    No historical dividends

    Recent Headlines From The Web

    Latest news, press releases, and media coverage about ALGS from trusted financial sources
      Boost your savings and earn 4.15% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
      All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

      ⓒ 2025 Financhle. All Rights Reserved.